Emerging Trends In Kidney Disorder Management Devices

Executive Summary

The kidney disorder management devices industry is evolving with innovations in wearable dialysis, AI-driven systems, and remote monitoring. Emerging technologies enhance patient mobility, and home-based care. These advancements address the growing prevalence of CKD, improve outcomes, and open new opportunities for personalized, tech-integrated kidney care solutions

Technological Advancements

Market Drivers

• RisingGlobal Prevalence of Kidney Disease and Associated Risk Factors

The increasing global burden of chronic kidney disease (CKD) is a primary driver behind the demand for advanced kidney disorder management devices. According to the data published by the National Kidney Foundation, 10% of the global population is impacted by chronic kidney disease. The prevalence is expected to rise further due to aging populations and the growing incidence of diabetes, hypertension, and cardiovascular diseases, all key risk factors for kidney dysfunction.

This surge in CKD cases is placing immense pressure on healthcare systems, creating a critical need for innovative devices that can support early diagnosis, ongoing monitoring, and more accessible treatment options such as portable or home-based dialysis. As a result, medical device companies are increasingly investing in technologies that can help manage CKD more effectively and improve patient outcomes.

• Increasing Focus On Clinical Trials

There is a growing focus on developing novel devices for managing kidney disorders, which has increased research activity and clinical trials. Academic institutions, industry innovators, and regulatory bodies are forming partnerships to move wearable and portable artificial kidney technologies from prototype to clinical reality.

Below is a table summarizing a few of the recently completed or ongoing studies in this field.

Source: ClinicalTrials.gov 

Competitive Scenario

Some of the key players operating in the kidney disorder management devices include:

Baxter ., Fresenius Medical Care AG, Nipro Europe Group Companies , Vantive, ProKidney Corp, Vivance, Renalyx Health Systems Pvt Ltd , Asahi Kasei Medical Co., Ltd., Mozarc Medical (Medtronic), Pollet Medical Group, D.Med Healthcare GmbH & Co. KG, F. Hoffmann-La Roche Ltd, Dialyfix, B. Braun SE, NIKKISO Medical Europe GmbH 

Recent Developments

Some of the strategies undertaken by key industry players operating in the kidney disorder management devices market are mentioned below:

• In October 2025, Roche, in partnership with KlinRisk, Inc., secured CE‑mark approval for the first AI‑based risk stratification tool to predict progressive decline in kidney function. This new algorithm will be rolled out as part of Roche’s chronic kidney disease (CKD) algorithm panel, embedded in the navify Algorithm Suite, to assist clinicians in managing CKD across all stages of the disease.

• In July 2025, Vantive, an organ‑therapy company, and Innovative Renal Care (IRC), which operates a broad network of kidney care programs across the U.S., signed a multi‑year strategic agreement. The collaboration aims to expand access to home dialysis therapies, enhance the patient therapy experience, and strengthen support for patients and care teams through improved technology‑enabled solutions.

• In June 2025, Fresenius Medical Care, a provider of products and services for renal patients, entered the second phase of its U.S. rollout for high‑volume hemodiafiltration (HVHDF) therapy. The company recently secured FDA 510(k) approval for an enhanced version of its 5008X CAREsystem, now equipped with hemodiafiltration capability and additional features. This regulatory milestone lays the foundation for its expanded commercialization in 2025 and paves the way for a full commercial launch in 2026.